Details for Patent: 9,107,900
✉ Email this page to a colleague
Which drugs does patent 9,107,900 protect, and when does it expire?
Patent 9,107,900 protects MULTAQ and is included in one NDA.
This patent has fifty-seven patent family members in twenty-eight countries.
Summary for Patent: 9,107,900
| Title: | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
| Abstract: | Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. |
| Inventor(s): | Radzik; Davide (Paris, FR), Van Eickels; Martin (Berlin, DE), Hamdani; Nacera (Colombes, FR), Gaudin; Christophe (Saint CLoud, FR) |
| Assignee: | SANOFI (Paris, FR) |
| Application Number: | 13/847,159 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,107,900 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,107,900
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | MULTAQ | dronedarone hydrochloride | TABLET;ORAL | 022425-001 | Jul 1, 2009 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS | ⤷ Try a Trial | |||
| Sanofi Aventis Us | MULTAQ | dronedarone hydrochloride | TABLET;ORAL | 022425-001 | Jul 1, 2009 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,107,900
International Family Members for US Patent 9,107,900
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 072950 | ⤷ Try a Trial | |||
| Argentina | 072951 | ⤷ Try a Trial | |||
| Australia | 2009252897 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
